{"id":"nktr-214","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Pyrexia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Immune-mediated adverse events"}]},"_chembl":{"chemblId":"CHEMBL4298058","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NKTR-214 is a modified IL-2 molecule designed to have reduced binding to the IL-2 receptor alpha (CD25) on regulatory T cells while maintaining activity on effector T cells and NK cells. This selective activation profile aims to promote anti-tumor immunity while minimizing immunosuppressive effects. It is typically used in combination with checkpoint inhibitors like nivolumab to enhance T cell proliferation and tumor infiltration.","oneSentence":"NKTR-214 is an engineered interleukin-2 (IL-2) cytokine that preferentially activates and expands CD8+ T cells and NK cells to enhance anti-tumor immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:08.439Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma (in combination with nivolumab)"},{"name":"Renal cell carcinoma (in combination with nivolumab)"},{"name":"Non-small cell lung cancer (in combination with nivolumab)"}]},"trialDetails":[{"nctId":"NCT03282344","phase":"PHASE2","title":"A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-09-12","conditions":"SARCOMA","enrollment":88},{"nctId":"NCT03635983","phase":"PHASE3","title":"A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-09-21","conditions":"Melanoma","enrollment":783},{"nctId":"NCT04209114","phase":"PHASE3","title":"A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2020-02-05","conditions":"Bladder Cancer, Bladder Tumor, Muscle-Invasive Bladder Cancer","enrollment":114},{"nctId":"NCT03835533","phase":"PHASE1","title":"Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations","status":"COMPLETED","sponsor":"Parker Institute for Cancer Immunotherapy","startDate":"2019-06-21","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":43},{"nctId":"NCT04936841","phase":"PHASE2","title":"Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2021-08-05","conditions":"Head and Neck Cancer","enrollment":5},{"nctId":"NCT04646044","phase":"PHASE1","title":"A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19","status":"COMPLETED","sponsor":"Nektar Therapeutics","startDate":"2020-11-13","conditions":"Covid-19, Coronavirus Disease 2019","enrollment":30},{"nctId":"NCT04540705","phase":"PHASE1","title":"A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2020-09-11","conditions":"Renal Cell Carcinoma","enrollment":30},{"nctId":"NCT04410445","phase":"PHASE3","title":"Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence","status":"TERMINATED","sponsor":"Nektar Therapeutics","startDate":"2020-07-27","conditions":"Melanoma, Melanoma Stage III, Melanoma Stage IV","enrollment":765},{"nctId":"NCT03548467","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer","status":"COMPLETED","sponsor":"Nykode Therapeutics ASA","startDate":"2018-04-04","conditions":"Locally Advanced or Metastatic Solid Tumours","enrollment":41},{"nctId":"NCT03729245","phase":"PHASE3","title":"A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)","status":"TERMINATED","sponsor":"Nektar Therapeutics","startDate":"2018-12-18","conditions":"Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma","enrollment":623},{"nctId":"NCT03785925","phase":"PHASE2","title":"A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer","status":"COMPLETED","sponsor":"Nektar Therapeutics","startDate":"2019-04-29","conditions":"Urinary Bladder Neoplasm, Neoplasm Metastasis","enrollment":192},{"nctId":"NCT04730349","phase":"PHASE1, PHASE2","title":"A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2021-06-03","conditions":"Ependymoma, Ewing Sarcoma, High-grade Glioma","enrollment":15},{"nctId":"NCT02983045","phase":"PHASE1, PHASE2","title":"A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors","status":"COMPLETED","sponsor":"Nektar Therapeutics","startDate":"2016-12-19","conditions":"Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer","enrollment":557},{"nctId":"NCT03138889","phase":"PHASE1, PHASE2","title":"Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"Nektar Therapeutics","startDate":"2017-06-09","conditions":"Non-Small Cell Lung Cancer","enrollment":162},{"nctId":"NCT03435640","phase":"PHASE1, PHASE2","title":"REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies","status":"TERMINATED","sponsor":"Nektar Therapeutics","startDate":"2018-03-15","conditions":"Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer","enrollment":64},{"nctId":"NCT03772288","phase":"PHASE1","title":"A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)","status":"WITHDRAWN","sponsor":"Calithera Biosciences, Inc","startDate":"2019-04-03","conditions":"Lymphoma, Non-Hodgkin","enrollment":""},{"nctId":"NCT04969861","phase":"PHASE2, PHASE3","title":"BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)","status":"TERMINATED","sponsor":"Nektar Therapeutics","startDate":"2022-03-09","conditions":"Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer","enrollment":1},{"nctId":"NCT04052204","phase":"PHASE1, PHASE2","title":"Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"Pfizer","startDate":"2019-12-30","conditions":"Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":3},{"nctId":"NCT03745807","phase":"PHASE1","title":"An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-04-09","conditions":"Advanced Cancer","enrollment":3},{"nctId":"NCT02869295","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Nektar Therapeutics","startDate":"2015-12","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":28},{"nctId":"NCT04955262","phase":"PHASE1","title":"A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab","status":"WITHDRAWN","sponsor":"Nektar Therapeutics","startDate":"2019-08","conditions":"Metastatic Melanoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":9,"reaction":"ACUTE KIDNEY INJURY"},{"count":9,"reaction":"MALIGNANT NEOPLASM PROGRESSION"},{"count":6,"reaction":"HYPOTENSION"},{"count":5,"reaction":"ATRIAL FIBRILLATION"},{"count":5,"reaction":"CEREBROVASCULAR ACCIDENT"},{"count":5,"reaction":"DEHYDRATION"},{"count":5,"reaction":"PYREXIA"},{"count":4,"reaction":"RESPIRATORY FAILURE"},{"count":3,"reaction":"DEATH"},{"count":3,"reaction":"HYPONATRAEMIA"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bempegaldesleukin","BMS-986321","CD122-Biased Cytokine","bempegaldesleukin","Bempegaldesleukin (BEMPEG)"],"phase":"phase_3","status":"active","brandName":"NKTR-214","genericName":"NKTR-214","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Biologic","firstApprovalDate":"","aiSummary":"NKTR-214 is an engineered interleukin-2 (IL-2) cytokine that preferentially activates and expands CD8+ T cells and NK cells to enhance anti-tumor immune responses. Used for Metastatic melanoma (in combination with nivolumab), Renal cell carcinoma (in combination with nivolumab), Non-small cell lung cancer (in combination with nivolumab).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":6,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}